Related Experiment Video
Updated: Dec 17, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Genomic profiling in renal cell carcinoma
Nazli Dizman1, Errol J Philip2, Sumanta K Pal3
1Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Abstract:
The treatment landscape of metastatic renal cell carcinoma (RCC) has been revolutionized over the past two decades, bringing forth an era in which more than a dozen therapeutic agents are now available to treat patients. As a consequence, personalized care has become a critical part of developing effective treatment guidelines and improving patient outcomes. One of the most important emerging aspects of precision medicine in cancer is matching patients and treatments based on the genomic characteristics of an individual and their tumour. Despite the lack of a single genomic predictor of treatment response or prognostication feature in RCC, emerging research suggests that the identification of such markers remains promising. Mutations in VHL and alterations in its downstream pathways are the mainstay of RCC development and progression. However, the predictive value of VHL mutations has been questioned. Further research has examined mutations in genes involved in chromosome remodelling (for example, PBRM1, BAP1 and SETD2), DNA methylation and DNA damage repair, all of which have been associated with clinical outcomes. Here, we provide a comprehensive overview of genomic evidence in the context of RCC and its potential predictive and prognostic value.
Insights
Genomic markers show promise for personalized metastatic renal cell carcinoma (RCC) treatment. Research explores gene mutations like VHL, PBRM1, BAP1, and SETD2 for predicting patient outcomes.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Metastatic renal cell carcinoma (RCC) treatment has advanced significantly.
- Personalized care based on tumor genomics is crucial for improving outcomes.
- Current genomic predictors for RCC treatment response are limited.
Purpose of the Study:
- To provide a comprehensive overview of genomic evidence in metastatic RCC.
- To explore the potential predictive and prognostic value of genomic alterations in RCC.
- To highlight emerging genomic markers for personalized RCC therapy.
Main Methods:
- Review of existing literature on genomic alterations in RCC.
- Analysis of mutations in key genes such as VHL, PBRM1, BAP1, and SETD2.
- Examination of downstream pathways and their association with clinical outcomes.
Main Results:
- VHL mutations are central to RCC development but their predictive value is debated.
- Mutations in genes involved in chromosome remodeling, DNA methylation, and repair are associated with clinical outcomes.
- No single genomic marker currently predicts treatment response or prognosis in RCC.
Conclusions:
- Genomic profiling holds promise for guiding personalized treatment strategies in RCC.
- Further research is needed to validate the predictive and prognostic value of identified genomic markers.
- Understanding the genomic landscape of RCC is essential for advancing precision oncology.
More Related Videos
06:29Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023